MicroRNAs (miRNAs) have recently found to be dysregulated in serum from multiple sclerosis (MS) patients. Cell free circulating miR-15b, -23a and 223 levels were analyzed by Real Time PCR in a cohort consisting of 30 serum samples from Relapsing Remitting MS patients at baseline (T0) and after three, six, nine and twelve months (T1, T2, T3, T4) after starting the treatment. A down-regulation of miRNA levels in patients at T0 compared with controls was present (p < 0.001). MiRNA levels slightly increased at T1 and this trend reached the statistical significance at T2 vs T0 and remains stable at T3 and T4. Our preliminary results suggest that aberrant levels of circulating miRNAs are recovered in fingolimod treated MS patients. Circulating miRNAs profiling could thus represent an easy detectable biomarker of disease and response to treatment.

Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis / C. Fenoglio, M. De Riz, A.M. Pietroboni, A. Calvi, M. Serpente, S.M.G. Cioffi, M. Arcaro, E. Oldoni, E. Scarpini, D. Galimberti. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - 299(2016 Oct 15), pp. 81-83. [10.1016/j.jneuroim.2016.08.017]

Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis

C. Fenoglio
;
M. De Riz
Secondo
;
A.M. Pietroboni;A. Calvi;M. Serpente;S.M.G. Cioffi;M. Arcaro;E. Oldoni;E. Scarpini
Penultimo
;
D. Galimberti
Ultimo
2016

Abstract

MicroRNAs (miRNAs) have recently found to be dysregulated in serum from multiple sclerosis (MS) patients. Cell free circulating miR-15b, -23a and 223 levels were analyzed by Real Time PCR in a cohort consisting of 30 serum samples from Relapsing Remitting MS patients at baseline (T0) and after three, six, nine and twelve months (T1, T2, T3, T4) after starting the treatment. A down-regulation of miRNA levels in patients at T0 compared with controls was present (p < 0.001). MiRNA levels slightly increased at T1 and this trend reached the statistical significance at T2 vs T0 and remains stable at T3 and T4. Our preliminary results suggest that aberrant levels of circulating miRNAs are recovered in fingolimod treated MS patients. Circulating miRNAs profiling could thus represent an easy detectable biomarker of disease and response to treatment.
Biomarker; Fingolimod; MicroRNA; Multiple sclerosis; Immunology and Allergy; Immunology; Neurology; Neurology (clinical)
Settore MED/26 - Neurologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
28. Fenoglio.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 284.56 kB
Formato Adobe PDF
284.56 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/502882
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 32
social impact